Olmesartan Ab (Olmesartan Medoxomil)

Olmesartan Ab belongs to the angiotensin II receptor blocker class and is used to manage elevated blood pressure.

• Essential hypertension: reduces systolic and diastolic blood pressure to target levels.
• Primary hypertension: helps achieve clinician‑defined blood pressure goals.
• High blood pressure: lowers cardiovascular risk by maintaining controlled blood pressure.

• Olmesartan Medoxomil is a selective antagonist of angiotensin II type 1 (AT1) receptors. By blocking these receptors, it prevents angiotensin II‑mediated vasoconstriction and aldosterone release, leading to relaxation of vascular smooth muscle, reduced peripheral resistance, and ultimately a decrease in blood pressure.

Olmesartan Ab may cause a range of adverse reactions.

Common Side Effects

• Dizziness or light‑headedness.
• Headache.
• Fatigue.
• Abdominal discomfort.
• Nasal congestion.

Serious or Rare Side Effects

• Angioedema (swelling of face, lips, tongue, or throat).
• Hyperkalemia (elevated blood potassium levels).
• Acute kidney injury or worsening renal function.
• Severe hypotension.
• Hepatic injury or abnormal liver enzymes.

Before initiating therapy, clinicians should consider several safety measures.

• Blood pressure monitoring: ensure target levels are reached without excessive drop.
• Renal function assessment: evaluate serum creatinine and eGFR periodically.
• Electrolyte checks: monitor potassium, especially if combined with potassium‑sparing agents.
• Pregnancy avoidance: drug is Category D; discontinue if pregnancy is confirmed.
• Elderly caution: start at lower dose and titrate slowly.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Olmesartan Ab can interact with several medicines; awareness of interaction severity guides management.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: increased risk of renal impairment.
• Potassium‑sparing diuretics or supplements: risk of hyperkalaemia.
• ACE inhibitors: additive effect on potassium and renal function.
• NSAIDs (e.g., ibuprofen, naproxen): may diminish antihypertensive effect and affect renal perfusion.
• Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance hypotensive response.
• Rifampin or other strong inducers: may reduce olmesartan plasma levels.
• CYP450 inhibitors (rare): potential modest increase in drug exposure.